AIVITA Biomedical CEO Dr. Hans Keirstead to Deliver Keynote on AI in Healthcare at McKenna Institute Digital Innovation Summit
IRVINE, Calif. – Jun. 12, 2023 – AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced that chairman and CEO Dr. Hans Keirstead will deliver a keynote at the Digital Innovation Summit, taking place June 12-13 in St. Andrews, New Brunswick, Canada.
Hosted by the University of New Brunswick’s McKenna Institute, the second annual Digital Innovation Summit will convene global experts, tech leaders and change-makers to define and accelerate New Brunswick’s digital future. The meeting hopes to accelerate action, innovation, and growth in the technology sector.
Dr. Keirstead will deliver one of two keynotes on the 12th, the other being given by Tessa Lyon, Director of Product Management at Instagram. The keynotes are being delivered in an evening session titled “How to create a movement for change.” In his keynote Dr. Keirstead will discuss the potential for AI to transform health care and the power of data trusts.
“AI is already beginning to transform everything from patient management to drug discovery in the healthcare sector,” said Dr. Keirstead. “I look forward to sharing some insights and predictions with this wonderful group.”
About AIVITA Biomedical
Founded in 2016 by pioneers in the cell therapy industry, AIVITA Biomedical, Inc. utilizes its expertise in stem cell growth and directed, high-purity differentiation to enable safe, efficient and economical manufacturing systems which support its therapeutic pipeline. Our cancer immunotherapy targets the seed of all cancers, tumor-initiating cells, with a unique pan-antigenic approach that targets all neoantigens specific to the patient’s cancer. Our patient-specific cancer treatments have shown great promise including eradicating tumors, without harmful side effects in melanoma, and renal cell cancer, and prolonging progression-free survival in glioblastoma. Our COVID-19 Vaccine Enabling Kit is targeted to emerging nations enabling point-of-care vaccine production in minimally equipped facilities by minimally trained third-party technicians.
Cautionary Note Regarding Forward-Looking Statements
This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as applicable. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations and assumptions, as well as other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date as of which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on a number of assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. This communication is neither an offer to sell nor a solicitation of an offer to buy any of the securities described herein.